HRD Score differs among molecular clusters. Despite lower levels in C1A clusters, metastatic cases exhibit elevated HRD Score, indicating its potential in refined metastatic risk. Elevated HRD Score following temozolomide treatment suggests a rationale for PARP inhibitor sequential or combination therapy.
Zhou et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: